DBV TECHNOLOGIES
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.
DBV TECHNOLOGIES
Industry:
Biopharma Biotechnology Health Care Health Diagnostics
Founded:
2002-01-01
Address:
Bagneux, Ile-de-France, France
Country:
France
Website Url:
http://www.dbv-technologies.com
Total Employee:
51+
Status:
Active
Contact:
+33 (0)1 55 42 78 78
Email Addresses:
[email protected]
Total Funding:
243.32 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Tag Manager WordPress Content Delivery Network Mobile Non Scaleable Content Euro IPv6 Yoast WordPress SEO Plugin JsDelivr
Similar Organizations
Bionanoplus
Bionanoplus focuses on the development of polymeric nanoparticles and microparticles as controlled release drug delivery systems.
Clinical Genomics Technologies
Clinical Genomics develops innovative products for colorectal cancer diagnosis.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
PET-Technology
PET-Technology is a federal network of medical centers for the diagnosis and treatment of cancer and the production of radiopharmaceuticals.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Braidwell
Braidwell investment in Post-IPO Equity - DBV Technologies
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Post-IPO Equity - DBV Technologies
Bpifrance
Bpifrance investment in Post-IPO Equity - DBV Technologies
Baker Brothers Advisors LLC
Baker Brothers Advisors LLC investment in Post-IPO Equity - DBV Technologies
RA Capital Management
RA Capital Management investment in Post-IPO Equity - DBV Technologies
Fairmount Funds Management
Fairmount Funds Management investment in Post-IPO Equity - DBV Technologies
Vivo Capital
Vivo Capital investment in Post-IPO Equity - DBV Technologies
Alto Invest
Alto Invest investment in Series C - DBV Technologies
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series C - DBV Technologies
ALK Abelló
ALK Abelló investment in Series C - DBV Technologies
Key Employee Changes
| Date | New article |
|---|---|
| 2020-02-06 | DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer |
Official Site Inspections
http://www.dbv-technologies.com Semrush global rank: 2.15 M Semrush visits lastest month: 9.32 K
- Host name: cloudproxy10055.sucuri.net
- IP address: 192.124.249.55
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "DBV Technologies"
DBV Technologies - Crunchbase Company Profile & Funding
DBV Technologies was founded in 2002 by Doctor Pierre-Henri Benhamou (specializing in Pediatric Gastroenterology), the engineer Bertrand Dupont (from the Arts et Métiers ParisTech in Paris) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris). The founders provided initial startup capital. Approximately €40M in venture funding was acquir…See details»
Contact Us - DBV Technologies
DBV Technologies Locations Corporate Headquarters France (DBV Technologies SA)ChâtillonDBV TechnologiesBâtiment IRO107 Av. de la République92320 ChâtillonPh ...See details»
Leadership - DBV Technologies
We have a dedicated and talented team of people across our organization, from our experienced leaders to our science-driven colleagues. Together, we are focused on discovering safe and …See details»
DBV Technologies - LinkedIn
DBV Technologies | 16,761 followers on LinkedIn. On a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™ | DBV Technologies is a global clinical ...See details»
Investor Overview - DBV Technologies
DBV Technologies is developing the VIASKIN ® patch, an investigational proprietary technology with broad potential clinical applications. The VIASKIN ® patch is based on epicutaneous …See details»
Our Science - DBV Technologies
Historically, food-allergic patients have seen limited pharmaceutical development in this field, with allergen avoidance and rescue medication in case of an allergic reaction as the current standard of care. At DBV, we are committed to …See details»
DBV Technologies - Overview, News & Similar companies
May 7, 2024 DBV Technologies contact info: Phone number: +33 155427878 Website: www.dbv-technologies.com What does DBV Technologies do? DBV Technologies is a French …See details»
Who Owns DBV Technologies – CANVAS, SWOT, PESTEL & BCG …
Dec 19, 2024 DBV Technologies, a company focusing on the development of innovative products for the diagnosis and treatment of food allergies, has an interesting ownership history …See details»
DBV Technologies S.A. (DBVT) - Yahoo Finance
See the company profile for DBV Technologies S.A. (DBVT) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
DBV Technologies Company Profile - Office Locations ... - Craft
Oct 29, 2024 DBV Technologies Summary. Company Summary. Overview. Epidemiological studies suggest that over half of Americans are sensitive to at least one allergen. …See details»
DBV Technologies - Funding, Financials, Valuation & Investors
DBV Technologies is registered under the ticker NASDAQ:DBVT . DBV Technologies is funded by 15 investors. Braidwell and Venrock Healthcare Capital Partners are the most recent investors.See details»
DBV Technologies Company Description - Stock Analysis
Jan 17, 2025 DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline …See details»
DBV Technologies - Contacts, Employees, Board Members
Organization. DBV Technologies . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 13. Number of …See details»
DBV Technologies | LinkedIn
DBV Technologies | 16,493 followers on LinkedIn. On a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™ | DBV Technologies is a …See details»
Mission, Vision & Core Values of DBV Technologies
Dec 19, 2024 DBV Technologies, a leading company in the field of food allergy diagnosis and treatment, is dedicated to developing innovative products that improve the lives of individuals …See details»
Dbv Technologies SA, DBV1:FRA profile - FT.com - Financial Times
Jun 6, 2024 DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called …See details»
Why DBV Technologies S.A.’s (DBVT) Stock Is Down 10.62%
1 day ago DBV Technologies S.A.’s price is currently up 0.22% so far this month. During the month of March, DBV Technologies S.A.’s stock price has reached a high of $5.300 and a low …See details»
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint …
Châtillon, France, February 25, 2025 DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock …See details»
2024 Annual General Meeting - DBV Technologies
Nous utilisons des cookies techniques nécessaires au bon fonctionnement du site internet. Si vous y consentez, nous et nos partenaires utiliserons également des cookies et autres …See details»
DBV Technologies: 32,5 millions de dollars de trésorerie, visibilité ...
1 day ago DBV Technologies (-4,74% à 0,86 euro) annonce que sa trésorerie et ses équivalents de trésorerie s’élevaient à 32,5 millions de dollars au 31 décembre 2024, contre 141,4 millions …See details»